$SGNT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Sagent Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Sagent Pharmaceuticals, Inc.. Get notifications about new insider transactions in Sagent Pharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Payment of Exercise | F | 21.84 | 388 | 8,474 | 25,703 | 26.1 K to 25.7 K (-1.49 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,134 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | M | 0.00 | 759 | 0 | 2,280 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Buy | M | 0.00 | 567 | 0 | 34,652 | 34.1 K to 34.7 K (+1.66 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Buy | M | 0.00 | 759 | 0 | 34,085 | 33.3 K to 34.1 K (+2.28 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,134 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Option Exercise | M | 0.00 | 759 | 0 | 2,280 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Buy | M | 0.00 | 567 | 0 | 1,893 | 1.3 K to 1.9 K (+42.76 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Buy | M | 0.00 | 759 | 0 | 1,326 | 567 to 1.3 K (+133.86 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,134 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | M | 0.00 | 759 | 0 | 2,280 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Buy | M | 0.00 | 567 | 0 | 6,996 | 6.4 K to 7 K (+8.82 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Buy | M | 0.00 | 759 | 0 | 6,429 | 5.7 K to 6.4 K (+13.39 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,134 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Option Exercise | M | 0.00 | 759 | 0 | 2,280 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Buy | M | 0.00 | 567 | 0 | 1,893 | 1.3 K to 1.9 K (+42.76 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Buy | M | 0.00 | 759 | 0 | 1,326 | 567 to 1.3 K (+133.86 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | M | 4.23 | 20,000 | 84,600 | 0 | |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Payment of Exercise | F | 21.75 | 441 | 9,592 | 35,032 | 35.5 K to 35 K (-1.24 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Payment of Exercise | F | 21.84 | 590 | 12,886 | 35,473 | 36.1 K to 35.5 K (-1.64 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 21.78 | 3,894 | 84,811 | 36,063 | 40 K to 36.1 K (-9.75 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Buy | M | 4.23 | 20,000 | 84,600 | 39,957 | 20 K to 40 K (+100.22 %) |
| Feb 24 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 22.05 | 4,638 | 102,268 | 19,957 | 24.6 K to 20 K (-18.86 %) |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | FEKETE MICHAEL | Director | Option Exercise | A | 0.00 | 3,720 | 0 | 3,720 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | A | 0.00 | 3,720 | 0 | 3,720 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Option Exercise | A | 0.00 | 3,720 | 0 | 3,720 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | A | 0.00 | 3,720 | 0 | 3,720 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Option Exercise | A | 0.00 | 3,720 | 0 | 3,720 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Greve Jeffrey W. | Vice President, Con ... | Option Exercise | A | 20.16 | 8,865 | 178,718 | 8,865 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Option Exercise | A | 20.16 | 8,865 | 178,718 | 8,865 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Grant | A | 0.00 | 4,960 | 0 | 26,091 | 21.1 K to 26.1 K (+23.47 %) |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | EVP, Nat. Accts and ... | Option Exercise | A | 20.16 | 8,865 | 178,718 | 8,865 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | EVP, Nat. Accts and ... | Grant | A | 0.00 | 4,960 | 0 | 38,333 | 33.4 K to 38.3 K (+14.86 %) |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | A | 20.16 | 10,638 | 214,462 | 10,638 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Grant | A | 0.00 | 5,952 | 0 | 24,595 | 18.6 K to 24.6 K (+31.93 %) |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | HUSSEY JAMES M | President | Option Exercise | A | 20.16 | 11,968 | 241,275 | 11,968 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | HUSSEY JAMES M | President | Grant | A | 0.00 | 6,696 | 0 | 6,696 | 0 to 6.7 K |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | EVP and CFO | Option Exercise | A | 20.16 | 10,638 | 214,462 | 10,638 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | EVP and CFO | Grant | A | 0.00 | 5,952 | 0 | 17,747 | 11.8 K to 17.7 K (+50.46 %) |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Option Exercise | A | 20.16 | 23,936 | 482,550 | 23,936 | |
| Feb 19 2014 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Grant | A | 0.00 | 13,393 | 0 | 681,501 | 668.1 K to 681.5 K (+2.00 %) |
| Jan 02 2014 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Payment of Exercise | F | 16.85 | 928 | 15,637 | 668,108 | 669 K to 668.1 K (-0.14 %) |
| Jan 02 2014 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Payment of Exercise | F | 16.85 | 347 | 5,847 | 21,131 | 21.5 K to 21.1 K (-1.62 %) |
| Jan 02 2014 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | EVP, Nat. Accts and ... | Payment of Exercise | F | 16.85 | 396 | 6,673 | 33,373 | 33.8 K to 33.4 K (-1.17 %) |
| Jan 02 2014 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | EVP and CFO | Payment of Exercise | F | 16.85 | 416 | 7,010 | 11,795 | 12.2 K to 11.8 K (-3.41 %) |
| Dec 26 2013 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Gift | G | 0.00 | 1,400 | 0 | 18,643 | 20 K to 18.6 K (-6.98 %) |
| Dec 26 2013 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Payment of Exercise | F | 16.85 | 506 | 8,526 | 20,043 | 20.5 K to 20 K (-2.46 %) |
| Oct 07 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.27 | 47,826 | 969,275 | 3,731,293 | 3.8 M to 3.7 M (-1.27 %) |
| Oct 03 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Buy | S | 20.32 | 40,020 | 813,118 | 3,779,119 | 3.7 M to 3.8 M (+1.07 %) |
| Oct 03 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.70 | 50,000 | 1,035,030 | 3,819,139 | 3.9 M to 3.8 M (-1.29 %) |
| Oct 01 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.38 | 25,000 | 509,615 | 3,869,139 | 3.9 M to 3.9 M (-0.64 %) |
| Oct 01 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.46 | 28,872 | 590,828 | 3,894,139 | 3.9 M to 3.9 M (-0.74 %) |
| Oct 01 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.60 | 10,000 | 206,000 | 3,923,011 | 3.9 M to 3.9 M (-0.25 %) |
| Oct 01 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.52 | 31,300 | 642,188 | 3,933,011 | 4 M to 3.9 M (-0.79 %) |
| Sep 27 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 20.37 | 67,965 | 1,384,304 | 3,964,311 | 4 M to 4 M (-1.69 %) |
| Sep 26 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 21.22 | 33,431 | 709,352 | 4,032,276 | 4.1 M to 4 M (-0.82 %) |
| Sep 26 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 21.50 | 14,693 | 315,839 | 4,065,707 | 4.1 M to 4.1 M (-0.36 %) |
| Sep 24 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 21.42 | 27,843 | 596,358 | 4,080,400 | 4.1 M to 4.1 M (-0.68 %) |
| Sep 24 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 21.96 | 91,714 | 2,013,819 | 4,108,243 | 4.2 M to 4.1 M (-2.18 %) |
| Sep 20 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 22.15 | 39,842 | 882,421 | 4,199,957 | 4.2 M to 4.2 M (-0.94 %) |
| Sep 20 2013 | SGNT | Sagent Pharmaceuti ... | MORGAN STANLEY INVESTMENT MANA ... | 10% Owner | Sell | S | 22.84 | 49,043 | 1,119,975 | 4,239,799 | 4.3 M to 4.2 M (-1.14 %) |
| Sep 18 2013 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Sell | S | 20.03 | 500,000 | 10,014,100 | 609,770 | 1.1 M to 609.8 K (-45.05 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Sell | S | 20.03 | 85,813 | 1,718,680 | 669,036 | 754.8 K to 669 K (-11.37 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | Vivo Ventures VI, LLC | 10% Owner | Sell | S | 21.25 | 4,529 | 96,241 | 30,405 | 34.9 K to 30.4 K (-12.96 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | Vivo Ventures VI, LLC | 10% Owner | Sell | S | 21.25 | 618,171 | 13,136,134 | 4,150,386 | 4.8 M to 4.2 M (-12.96 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | Vivo Ventures V, LLC | 10% Owner | Sell | S | 21.25 | 6,252 | 132,855 | 41,980 | 48.2 K to 42 K (-12.96 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | Vivo Ventures V, LLC | 10% Owner | Sell | S | 21.25 | 532,765 | 11,321,256 | 3,576,966 | 4.1 M to 3.6 M (-12.96 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Sell | S | 21.25 | 622,700 | 13,232,375 | 4,180,791 | 4.8 M to 4.2 M (-12.96 %) |
| Sep 17 2013 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Sell | S | 21.25 | 539,017 | 11,454,111 | 3,618,946 | 4.2 M to 3.6 M (-12.96 %) |
| Aug 13 2013 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Sell | S | 23.69 | 1,000 | 23,690 | 21,478 | 22.5 K to 21.5 K (-4.45 %) |
| Jul 15 2013 | SGNT | Sagent Pharmaceuti ... | FEKETE MICHAEL | Director | Option Exercise | A | 0.00 | 2,366 | 0 | 2,366 | |
| May 13 2013 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | M | 4.23 | 1,276 | 5,397 | 0 | |
| May 13 2013 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Buy | M | 4.23 | 1,276 | 5,397 | 5,670 | 4.4 K to 5.7 K (+29.04 %) |
| Mar 26 2013 | SGNT | Sagent Pharmaceuti ... | HUSSEY JAMES M | President | Option Exercise | A | 17.29 | 100,000 | 1,729,000 | 100,000 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,701 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | A | 0.00 | 3,039 | 0 | 3,039 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Buy | M | 0.00 | 567 | 0 | 4,394 | 3.8 K to 4.4 K (+14.82 %) |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,701 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | A | 0.00 | 3,039 | 0 | 3,039 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Buy | M | 0.00 | 567 | 0 | 33,326 | 32.8 K to 33.3 K (+1.73 %) |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,701 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Option Exercise | A | 0.00 | 3,039 | 0 | 3,039 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Buy | M | 0.00 | 567 | 0 | 567 | 0 to 567 |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Option Exercise | M | 0.00 | 567 | 0 | 1,701 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Option Exercise | A | 0.00 | 3,039 | 0 | 3,039 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Buy | M | 0.00 | 567 | 0 | 567 | 0 to 567 |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Greve Jeffrey W. | Vice President, Con ... | Option Exercise | A | 16.45 | 8,604 | 141,536 | 8,604 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Option Exercise | A | 16.45 | 8,499 | 139,809 | 8,499 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | Corporate VP, Sales | Grant | A | 0.00 | 4,924 | 0 | 22,478 | 17.6 K to 22.5 K (+28.05 %) |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | EVP, Nat. Accts and ... | Option Exercise | A | 16.45 | 12,067 | 198,502 | 12,067 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | EVP, Nat. Accts and ... | Grant | A | 0.00 | 6,991 | 0 | 33,769 | 26.8 K to 33.8 K (+26.11 %) |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | A | 16.45 | 12,067 | 198,502 | 12,067 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Grant | A | 0.00 | 6,991 | 0 | 20,549 | 13.6 K to 20.5 K (+51.56 %) |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | EVP and CFO | Option Exercise | A | 16.45 | 12,067 | 198,502 | 12,067 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | EVP and CFO | Grant | A | 0.00 | 6,991 | 0 | 12,211 | 5.2 K to 12.2 K (+133.93 %) |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Option Exercise | A | 16.45 | 27,282 | 448,789 | 27,282 | |
| Feb 25 2013 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Grant | A | 0.00 | 15,805 | 0 | 754,849 | 739 K to 754.8 K (+2.14 %) |
| Dec 31 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Gift | G | 0.00 | 1,300 | 0 | 13,558 | 14.9 K to 13.6 K (-8.75 %) |
| Dec 13 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Gift | G | 0.00 | 3,000 | 0 | 14,858 | 17.9 K to 14.9 K (-16.80 %) |
| Nov 16 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | M | 4.23 | 17,338 | 73,340 | 0 | |
| Nov 16 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | M | 4.23 | 1,800 | 7,614 | 17,338 | |
| Nov 16 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 14.38 | 9,000 | 129,420 | 22,753 | 31.8 K to 22.8 K (-28.34 %) |
| Nov 16 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Buy | M | 4.23 | 17,338 | 73,340 | 31,753 | 14.4 K to 31.8 K (+120.28 %) |
| Nov 16 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 14.56 | 1,000 | 14,560 | 14,415 | 15.4 K to 14.4 K (-6.49 %) |
| Nov 16 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Buy | M | 4.23 | 1,800 | 7,614 | 15,415 | 13.6 K to 15.4 K (+13.22 %) |
| Nov 21 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | M | 4.23 | 4,243 | 17,948 | 19,999 | |
| Nov 21 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Buy | M | 4.23 | 4,243 | 17,948 | 17,858 | 13.6 K to 17.9 K (+31.16 %) |
| Nov 20 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 14.64 | 6,867 | 100,533 | 13,615 | 20.5 K to 13.6 K (-33.53 %) |
| Nov 20 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 14.68 | 2,271 | 33,338 | 20,482 | 22.8 K to 20.5 K (-9.98 %) |
| Sep 11 2012 | SGNT | Sagent Pharmaceuti ... | Yu Chen-Ming | Interim COO | Option Exercise | A | 15.52 | 105,000 | 1,629,600 | 105,000 | |
| Aug 28 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Executive VP, Opera ... | Option Exercise | M | 4.31 | 12,759 | 54,991 | 12,759 | |
| Aug 28 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Executive VP, Opera ... | Option Exercise | M | 4.23 | 2,552 | 10,795 | 0 | |
| Aug 28 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Executive VP, Opera ... | Option Exercise | M | 4.31 | 638 | 2,750 | 638 | |
| Aug 28 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Executive VP, Opera ... | Buy | M | 4.31 | 12,759 | 54,991 | 26,778 | 14 K to 26.8 K (+91.01 %) |
| Aug 28 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Executive VP, Opera ... | Buy | M | 4.23 | 2,552 | 10,795 | 14,019 | 11.5 K to 14 K (+22.26 %) |
| Aug 28 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Executive VP, Opera ... | Buy | M | 4.31 | 638 | 2,750 | 11,467 | 10.8 K to 11.5 K (+5.89 %) |
| Jun 04 2012 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | M | 4.23 | 3,190 | 13,494 | 0 | |
| Jun 04 2012 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Buy | M | 4.23 | 3,190 | 13,494 | 32,759 | 29.6 K to 32.8 K (+10.79 %) |
| May 29 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Sell | S | 15.86 | 7,000 | 111,020 | 13,615 | 20.6 K to 13.6 K (-33.96 %) |
| May 18 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Buy | P | 15.69 | 2,000 | 31,380 | 20,615 | 18.6 K to 20.6 K (+10.74 %) |
| May 14 2012 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | M | 4.23 | 1,275 | 5,393 | 1,276 | |
| May 14 2012 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Buy | M | 4.23 | 1,275 | 5,393 | 3,827 | 2.6 K to 3.8 K (+49.96 %) |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Option Exercise | M | 4.31 | 15,948 | 68,736 | 47,845 | |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Option Exercise | M | 4.23 | 19,138 | 80,954 | 0 | |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Buy | M | 4.31 | 15,948 | 68,736 | 739,044 | 723.1 K to 739 K (+2.21 %) |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Buy | M | 4.23 | 19,138 | 80,954 | 723,096 | 704 K to 723.1 K (+2.72 %) |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | M | 4.23 | 3,190 | 13,494 | 3,189 | |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Buy | M | 4.23 | 3,190 | 13,494 | 29,569 | 26.4 K to 29.6 K (+12.09 %) |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | M | 4.23 | 1,277 | 5,402 | 2,551 | |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Gift | G | 0.00 | 1,000 | 0 | 2,000 | 3 K to 2 K (-33.33 %) |
| Apr 19 2012 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Buy | M | 4.23 | 1,277 | 5,402 | 2,552 | 1.3 K to 2.6 K (+100.16 %) |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | Chief Financial Off ... | Option Exercise | A | 22.04 | 9,330 | 205,633 | 9,330 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Singer Jonathon M | Chief Financial Off ... | Grant | A | 0.00 | 5,220 | 0 | 5,220 | 0 to 5.2 K |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Yu Chen-Ming | Director | Option Exercise | A | 0.00 | 2,268 | 0 | 2,268 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Sperans James | Director | Option Exercise | A | 0.00 | 2,268 | 0 | 2,268 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | KUNG FRANK | Director | Option Exercise | A | 0.00 | 2,268 | 0 | 2,268 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Krizman Anthony | Director | Option Exercise | A | 0.00 | 2,268 | 0 | 2,268 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | FLANAGAN ROBERT J | Director | Option Exercise | A | 0.00 | 2,268 | 0 | 2,268 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Behrens Mary Taylor | Director | Option Exercise | A | 0.00 | 2,268 | 0 | 2,268 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Hebeda Dave | Vice President, Fin ... | Option Exercise | A | 22.04 | 4,380 | 96,535 | 4,380 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Senior VP, Operatio ... | Option Exercise | A | 22.04 | 7,950 | 175,218 | 7,950 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Patterson Albert | Senior VP, Operatio ... | Grant | A | 0.00 | 4,450 | 0 | 10,829 | 6.4 K to 10.8 K (+69.76 %) |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | VP, Sales and Marke ... | Option Exercise | A | 22.04 | 6,570 | 144,803 | 6,570 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Drake Lorin | VP, Sales and Marke ... | Grant | A | 0.00 | 3,680 | 0 | 17,554 | 13.9 K to 17.6 K (+26.52 %) |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Pauli Ronald | Chief Financial Off ... | Option Exercise | A | 22.04 | 6,570 | 144,803 | 6,570 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Pauli Ronald | Chief Financial Off ... | Grant | A | 0.00 | 3,680 | 0 | 3,680 | 0 to 3.7 K |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Option Exercise | A | 22.04 | 9,330 | 205,633 | 9,330 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | Logerfo Michael | Chief Legal Officer | Grant | A | 0.00 | 5,220 | 0 | 18,615 | 13.4 K to 18.6 K (+38.97 %) |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Option Exercise | A | 22.04 | 21,090 | 464,824 | 21,090 | |
| Feb 24 2012 | SGNT | Sagent Pharmaceuti ... | YORDON JEFFREY | Chief Executive Off ... | Grant | A | 0.00 | 11,800 | 0 | 703,958 | 692.2 K to 704 K (+1.70 %) |